期刊文献+

多重耐药菌株种类和危险因素相关性研究 被引量:7

Clinical Study on the Relationship Between the Species of Multi Drug Resistant Organisms and Risk Factors
下载PDF
导出
摘要 目的探讨多重耐药菌(Multi drug resistant organisms,MDRO)的分布特点、抗菌药物的敏感性、菌株种类与危险因素的相关性。方法回顾性分析2012年10月1日—2013年6月30日159例MDRO感染患者的临床资料,分析MDRO的分布特点、抗菌药物的敏感性,MDRO种类与危险因素的相关性。结果 MDRO主要分布在下呼吸道;主要细菌依次为鲍曼不动杆菌、肺炎克雷伯菌、大肠埃希菌、金黄色葡萄球菌、铜绿假单胞菌。碳氢霉烯类抗生素的应用容易引起多重耐药的鲍曼不动杆菌和金黄色葡萄球菌感染。气管插管和气管切开更易发生多种MDRO感染。结论 MDRO呈现不同的耐药性和难治性;碳氢霉烯类抗生素的应用容易引起多重耐药的鲍曼不动杆菌和金黄色葡萄球菌感染。气管插管和气管切开是发生多种MDRO感染的危险因素。 Objective To investigate the distribution characteristics, antibiotic susceptibility, correlation between the strains and risk factors of multi drug resistant organisms (MDRO). Methods We retrospectively surveyed the clinical data of 159 patients suffered MDRO infection and analyzing the distribution characteristics, antibiotic susceptibility, correlation between the strains and risk factors of MDRO. Results The MDRO were mainly distributed in the lower respiratory tract. The main bacteria were Acinetobaeter baumaunii ( Ab ) , Klebsiella pneumoniae ( Kpn ) , Escherichia eoli ( E. eoli ) , Staphylococcus aureus (SA) and Pseudomonas aeruginosa (PA). Application of carbapenem antibiotics more easily caused infection of multidrug-resistant Acinetobacter baumannii and Staphylococcus aureus. Multiple MDRO infection was related to endotracheal intubation and tracheotomy. Conclusion MDRO presents different resistance and refractory. Application of carbapenem antibiotics more easily causes infection of multidrug-resistant Acinetobacter baumannii and Staphylococcus aureus. Endotracheal intubation and tracheotomy is risk factor of Multiple MDRO infection.
出处 《创伤与急危重病医学》 2014年第6期325-328,共4页 Trauma and Critical Care Medicine
关键词 多重耐药菌 分布特点 抗菌药物敏感性 危险因素 Multi drug resistant organisms distribution characteristics antibiotic sensitivity risk factors
  • 相关文献

参考文献6

二级参考文献31

  • 1[2]Livermore DM. Clinical significance of beta-lactamase induction and stable derepression in Gram-negative rods[J]. Eur J Clin Microbiol,1987,6(4):439-445.
  • 2[3]Murray BE. Vancomycin-resistant enterococcal infections[J]. N Engl J Med,2000,342(10):710-721.
  • 3[5]Ambrose PG, Owens RCJr. New antibiotics in pulmonary and critical care medicine: focus on advanced generation quinolones and cephalosporins[J]. Resp Crit Care Med,2000,21(1):19-32.
  • 4[6]Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting[J]. Crit Care, 2001, 5(4): 189-195.
  • 5Moellering RC JC. Vancomycin- resistant enterococci[J]. Clin Infert Dic, 1998,26:1196.
  • 6Wang H, Chen M, Ni Y, et al. Antimierobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. Int J Antimicrob Agents, 2010, 35..227- 234.
  • 7Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to olistin in Acinetobacter baumannii associated with mutations in Lhe PmrAB two-component system. Antimicrob Agents Chemother, .009, 53:3628-3634.
  • 8Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving muhidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother, 2009, 63:775-780.
  • 9Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis, 2006, 43:518-524.
  • 10Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis, 2008, 46:862-867.

共引文献230

同被引文献87

引证文献7

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部